Ovid Therapeutics (OVID) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - As of December 31, 2025, Ovid Therapeutics reported $90.4 million in cash equivalents and marketable securities [42] - The company announced a PIPE financing with gross proceeds totaling $60 million, which is expected to extend the cash runway into the second half of 2028 [42] - If the Series A warrants are fully exercised, the pro forma cash runway could extend well into 2029 [42] Business Line Data and Key Metrics Changes - The company received regulatory clearance for OV4071, the first-ever oral KCC2 direct activator, a quarter earlier than expected [5] - OV329, a next-generation GABA aminotransferase inhibitor, has shown no serious adverse events at the 7-milligram dose, indicating a strong safety and tolerability profile [5][13] - The company is launching additional studies for OV329 in infantile spasms and seizures associated with tuberous sclerosis complex, supported by new capital [7][8] Market Data and Key Metrics Changes - The market opportunity for OV329 is significant, especially in treating conditions like infantile spasms and tuberous sclerosis complex, where current treatment options are limited [24][27] - The peak sales of Sabril (Vigabatrin) reached over $320 million, indicating a substantial market potential for a safer alternative like OV329 [79] Company Strategy and Development Direction - Ovid Therapeutics aims to develop gentler, better medicines for the brain, focusing on controlling neural hyperexcitability through small molecule programs [9] - The company plans to initiate a phase 1 study for OV4071 and a ketamine challenge study to demonstrate proof of mechanism [33][40] - The strategy includes developing differentiated formulations for adult and pediatric populations, allowing for differential pricing based on the specific needs of each community [70] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of OV329 to be used earlier and longer in treatment, which could change the trajectory of diseases for children with severe conditions [78] - The company is optimistic about the upcoming milestones and catalysts, indicating a busy couple of years ahead [37] Other Important Information - Ovid Therapeutics does not plan to host regular quarterly earnings calls moving forward, indicating a shift in communication strategy [4] - The company is preparing for a KCC2 day to provide more insights into the KCC2 portfolio and its therapeutic potential [36] Q&A Session Summary Question: Can you provide more detail on OV329 and the visual monitoring? - Management confirmed that optic and retinal monitoring will continue through phase 2 and pivotal studies to ensure robust safety data [50] Question: What are the key endpoints for the planned phase two design for OV329? - The phase 2 study will target adults with treatment-resistant focal onset seizures, focusing on traditional endpoints like percent reduction in seizures and CGI endpoints [59] Question: What type of patients will be enrolled in the open-label photosensitive epilepsy study? - The study will enroll adults with diagnosed epilepsy and documented photosensitivity, using intermittent photic stimulation for screening [67] Question: How does the company plan to address long-term clinical development for OV329? - Management indicated that OV329 has broad therapeutic utility and that evidence will inform potential expansions into other indications [91]